scispace - formally typeset
H

Heval M. Kelli

Researcher at Emory University

Publications -  56
Citations -  2021

Heval M. Kelli is an academic researcher from Emory University. The author has contributed to research in topics: Coronary artery disease & Heart failure. The author has an hindex of 19, co-authored 54 publications receiving 1238 citations. Previous affiliations of Heval M. Kelli include Cardiovascular Institute of the South & Morehouse School of Medicine.

Papers
More filters
Journal ArticleDOI

Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions.

TL;DR: The current state of knowledge on the impact of SES on the incidence, treatment, and outcomes of CVD in high-income societies is reviewed and future research directions aimed at the elimination of these adverse factors, and the integration of measures of S ES into the customization of cardiovascular treatment are suggested.
Journal ArticleDOI

The role of mHealth for improving medication adherence in patients with cardiovascular disease: a systematic review

TL;DR: Current evidence suggests that mHealth tools can improve medication adherence in patients with cardiovascular diseases, however, high-quality clinical trials of sufficient size and duration are needed to move the field forward and justify use in routine care.
Journal ArticleDOI

The Wild Wild West: A Framework to Integrate mHealth Software Applications and Wearables to Support Physical Activity Assessment, Counseling and Interventions for Cardiovascular Disease Risk Reduction

TL;DR: The validity, utility and feasibility of implementing mHealth technology in clinical settings are reviewed and an organizational framework to support PA assessment, counseling and referrals to community resources for CVD risk reduction interventions is proposed.
Journal ArticleDOI

The Prognostic Significance of Diabetes and Microvascular Complications in Patients With Heart Failure With Preserved Ejection Fraction

TL;DR: Diabetes is associated with adverse cardiovascular outcomes in HFpEF, and the inherent risk of adverse outcomes inHFpEF patients with diabetes varies by the presence of microvascular complications.